Genetic variation in the beta-2 adrenergic receptor (ADRB2) predicts functional gastrointestinal diagnoses and poorer health-related quality of life

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 3, 2013, Pages 313-323

  Kushnir, V M ^a   Cassell, B ^a   Gyawali, C P ^a   Newberry, R D ^a   Kibe, P ^a   Nix, B D ^a   Sabzpoushan, A ^a   Kanuri, N D ^a   Sayuk, G S ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR;

ADULT; ALLELE; ARTICLE; BETA 2 ADRENERGIC RECEPTOR GENE; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; THORAX PAIN;

BIOLOGICAL MARKERS; FEMALE; GASTROINTESTINAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY OF LIFE; RECEPTORS, ADRENERGIC, BETA-2; SEVERITY OF ILLNESS INDEX;

EID: 84879721631     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12378     Document Type: Article

References (32)

1. Longstreth G, Thompson W, Chey W, Houghton L, Mearin F, Spiller R,. Functional bowel disorders. In:, Drossman D, Corazziari E, Delvaux M, Spiller R, Talley N, Thompson W, Whitehead W, eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon, 2006; 487-555.
2. Mayer EA,. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008; 358: 1692-9.
3. Ohman L, Simren M,. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
4. Chang L,. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011; 140: 761-5.
5. Saito YA, Mitra N, Mayer EA,. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 2010; 138: 1276-85.
6. Gupta V, Sheffield D, Verne GN,. Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig Dis Sci 2002; 47: 1716-22.
7. Whitehead WE, Palsson O, Jones KR,. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 1140-56.
8. Tsigos C, Chrousos GP,. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002; 53: 865-71.
9. Martinez-Lavin M,. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. Arthritis Res Ther 2007; 9: 216.
10. Argoff C,. Mechanisms of pain transmission and pharmacologic management. Curr Med Res Opin 2011; 27: 2019-31.
11. Tchivileva IE, Lim PF, Smith SB, et al,. Effect of catechol-O- methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics 2010; 20: 239-48.
12. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W,. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 2007; 128: 199-208.
13. Diatchenko L, Anderson AD, Slade GD, et al,. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 449-62.
14. Hocking LJ, Smith BH, Jones GT, Reid DM, Strachan DP, Macfarlane GJ,. Genetic variation in the beta2-adrenergic receptor but not catecholamine-O- methyltransferase predisposes to chronic pain: results from the 1958 British Birth Cohort Study. Pain 2010; 149: 143-51.
15. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, et al,. Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum 2009; 60: 2169-73.
16. Drossman DACE, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead W, eds. Rome III: the Functional Gastrointestinal Disorders. McLean: Degnon Associates, Inc, 2006.
17. Winslow ER, Clouse RE, Desai KM, et al,. Influence of spastic motor disorders of the esophageal body on outcomes from laparoscopic antireflux surgery. Surg Endosc 2003; 17: 738-45.
18. Edwards AWF,. Fundamentals of Mathematical Genetics. 2nd ed. Cambridge, U.K.: Cambridge University Press, 2000.
19. Cain KC, Jarrett ME, Burr RL, Hertig VL, Heitkemper MM,. Heart rate variability is related to pain severity and predominant bowel pattern in women with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 110-8.
20. Burr RL, Heitkemper M, Jarrett M, Cain KC,. Comparison of autonomic nervous system indices based on abdominal pain reports in women with irritable bowel syndrome. Biol Res Nurs 2000; 2: 97-106.
21. Posserud I, Agerforz P, Ekman R, Bjornsson ES, Abrahamsson H, Simren M,. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004; 53: 1102-8.
22. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D,. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum 2000; 29: 217-27.
23. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA,. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001; 121: 799-804.
24. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G,. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998; 93: 1311-7.
25. Kim HJ, Camilleri M, Carlson PJ, et al,. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53: 829-37.
26. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV,. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-3.
27. Bradley LA,. Pathophysiology of fibromyalgia. Am J Med 2009; 122 (12 Suppl): S22-30.
28. Frissora CL, Koch KL,. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005; 7: 264-71.
29. Light KC, Bragdon EE, Grewen KM, Brownley KA, Girdler SS, Maixner W,. Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder. J Pain 2009; 10: 542-52.
30. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E,. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1337-45.
31. Fielding JF,. Timolol treatment in the irritable bowel syndrome. Digestion 1981; 22: 155-8.
32. McIntyre AS, Burnham WR, Thompson DG,. Atenolol in irritable bowel syndrome. Lancet 1988; 1: 67.